Attune is a digital health therapeutic device that provides Cognitive Behavioral Stress Management (CBSM) to treat anxiety and depressive symptoms in adult cancer patients. Due to the COVID-19 public health emergency, the US Food and Drug Administration (FDA) has determined that digital therapeutic devices such as attune can be distributed and used prior to FDA review to improve the mental health and well-being of patients. Attune provides adjunctive (supporting) therapy and should not be solely or primarily relied upon to treat psychiatric conditions related to the experience of cancer; attune is not standalone therapy. Contact your healthcare provider in case of a medical or psychiatric emergency. Attune is being evaluated in clinical trials and is being reviewed by FDA.